12:00 AM
 | 
Aug 05, 2013
 |  BC Week In Review  |  Company News  |  Deals

Cubist, Trius deal

Cubist will acquire fellow infectious disease company Trius in a cash and contingent value right (CVR) deal worth up to $818 million. Trius shareholders will receive $13.50 in cash, which Cubist and Trius said values the latter at about $707 million. The price is a 15% premium to Trius' close of $11.71 on July 30,...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >